Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B

Hepatology

Volumn 66, Issue 6, 2017, Pages 2066-2077

  Hong, Xupeng ^a   Kim, Elena S ^b   Guo, Haitao ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULAR DNA; HISTONE; IMMUNOMODULATING AGENT; VIRUS DNA;

CHRONIC HEPATITIS B; DNA METHYLATION; EPIGENETICS; GENE TARGETING; GENE THERAPY; HEPATITIS B VIRUS; HISTONE MODIFICATION; HUMAN; IMMUNOTHERAPY; LIFE CYCLE; MINICHROMOSOME; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS GENE; GENETIC EPIGENESIS; GENETICS; METABOLISM; VIROLOGY;

DNA, CIRCULAR; DNA, VIRAL; EPIGENESIS, GENETIC; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS;

EID: 85034431696     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29479     Document Type: Review

References (74)

1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-352.
2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546-1555.
3. Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, Guo JT. Chronic hepatitis B: What should be the goal for new therapies? Antiviral Res 2013;98:27-34.
4. Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo J, et al. Present and future therapies of hepatitis B: From discovery to cure. Hepatology 2015;62:1893-1908.
5. Bitton Alaluf M, Shlomai A. New therapies for chronic hepatitis B. Liver Int 2016;36:775-782.
6. Sung JJY, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890-1897.
7. Werle–Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758.
8. Dawson MA. The cancer epigenome: concepts, challenges, and therapeutic opportunities. Science 2017;355:1147-1152.
9. Bock CT, Schranz P, Schröder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994;8:215-229.
10. Bock CT, Schwinn S, Locarnini S, Fyfe J, Manns MP, Trautwein C, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 2001;307:183-196.
11. Byrd JC. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2004;105:959-967.
12. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012;1:e00049.
13. Huang HC, Chen CC, Chang WC, Tao MH, Huang C. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol 2012;86:9443-9453.
14. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology 2015;479:672-686.
15. Shi L, Li S, Shen F, Li H, Qian S, Lee DH, et al. Characterization of nucleosome positioning in hepadnaviral covalently closed circular DNA minichromosomes. J Virol 2012;86:10059-10069.
16. Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001;75:311-322.
17. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997;276:60-66.
18. Guo JT, Zhou H, Liu C, Aldrich C, Saputelli J, Whitaker T, et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000;74:1495-1505.
19. Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162. [Epub ahead of print]
20. Lutgehetmann M, Volz T, Köpke A, Broja T, Tigges E, Lohse AW, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010;52:16-24.
21. Chisari F V>, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010;58:258-266.
22. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694-1701.
23. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future directions. Gastroenterology 2017;152:1297-1309.
24. Schübeler D. Function and information content of DNA methylation. Nature 2015;517:321-326.
25. Vivekanandan P, Thomas D, Torbenson M. Hepatitis B viral DNA is methylated in liver tissues. J Viral Hepat 2008;15:103-107.
26. Zhang Y, Li C, Zhang Y, Zhu H, Kang Y, Liu H, et al. Comparative analysis of CpG islands among HBV genotypes. PLoS One 2013;8:e56711.
27. Zhang Y, Mao R, Yan R, Cai D, Zhang Y, Zhu H, et al. Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection. PLoS One 2014;9:e110442.
28. Jain S, Chang TT, Chen S, Boldbaatar B, Clemens A, Lin SY, et al. Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. Sci Rep 2015;5:10478.
29. Vivekanandan P, Daniel HD, Kannangai R, Martinez-Murillo F, Torbenson M. Hepatitis B virus replication induces methylation of both host and viral DNA. J Virol 2010;84:4321-4329.
30. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013;13:123-135.
31. Barlow DP. Methylation and imprinting: from host defense to gene regulation? Science 1993;260:309-311.
32. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
33. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, et al. New nomenclature for chromatin-modifying enzymes. Cell 2007;131:633-636.
34. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011;17:330-339.
35. Bedford MT, Richard S. Arginine methylation: an emerging regulatorof protein function. Mol Cell 2005;18:263-272.
36. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012;122:529-537.
37. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006;130:823-837.
38. Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 2009;106:19975-19979.
39. Benhenda S, Ducroux A, Rivière L, Sobhian B, Ward MD, Dion S, et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol 2013;87:4360-4371.
40. Zhang W, Chen J, Wu M, Zhang X, Zhang M, Yue L, et al. PRMT5 restricts hepatitis B virus replication via epigenetic repression of cccDNA transcription and interference with pgRNA encapsidation. Hepatology 2017;66:398-415.
41. Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 2013;9:e1003613.
42. Tropberger P, Mercier A, Robinson M, Zhong W, Ganem DE, Holdorf M. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci USA 2015;112:E5715-E5724.
43. Ananthanarayanan M, Li Y, Surapureddi S, Balasubramaniyan N, Ahn J, Goldstein JA, et al. Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis. Am J Physiol Gastrointest Liver Physiol 2011;300:G771-G781.
44. Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet 2016;17:487-500.
45. Tropberger P, Pott S, Keller C, Kamieniarz-Gdula K, Caron M, Richter F, et al. Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. Cell 2013;152:859-872.
46. Pradeepa MM, Grimes GR, Kumar Y, Olley G, Taylor GC, Schneider R, et al. Histone H3 globular domain acetylation identifies a new class of enhancers. Nat Genet 2016;48:681-686.
47. Cougot D, Wu Y, Cairo S, Caramel J, Renard CA, Lévy L, et al. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J Biol Chem 2007;282:4277-4287.
48. Rivière L, Gerossier L, Ducroux A, Dion S, Deng Q, Michel ML, et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol 2015;63:1093-1102.
49. Decorsière A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature 2016;531:386-389.
50. Murphy CM, Xu Y, Li F, Nio K, Reszka-Blanco N, Li X, et al. Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication. Cell Rep 2016;16:2846-2854.
51. Mitra B, Guo H. Hepatitis B virus X protein crosses out Smc5/6 complex to maintain covalently closed circular DNA transcription. Hepatology 2016;64:2246-2249.
52. Deeks SG. HIV: shock and kill. Nature 2012;487:439-440.
53. Ghosh SK, Perrine SP, Williams RM, Faller DV. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 2012;119:1008-1017.
54. Shim YH, Yoon GS, Choi HJ, Chung YH, Yu E. p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett 2003;190:213-219.
55. Krawczyk J, Keane N, Freeman CL, Swords R, O'Dwyer M, Giles FJ. 5-Azacytidine for the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 2013;14:1255-1268.
56. Ahuja N, Sharma AR, Baylin SB. Epigenetic therapeutics: a new weapon in the war against cancer. Annu Rev Med 2016;67:73-89.
57. Henning SM, Wang P, Carpenter CL, Heber D. Epigenetic effects of green tea polyphenols in cancer. Epigenomics 2013;5:729-741.
58. Huang HC, Tao MH, Hung TM, Chen JC, Lin ZJ, Huang C. (−)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res 2014;111:100-111.
59. Zhong L, Hu J, Shu W, Gao B, Xiong S. Epigallocatechin-3-gallate opposes HBV-induced incomplete autophagy by enhancing lysosomal acidification, which is unfavorable for HBV replication. Cell Death Dis 2015;6:e1770.
60. Zheng DL, Zhang L, Cheng N, Xu X, Deng Q, Teng XM, et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 2009;50:377-387.
61. Chiappinelli KB, Zahnow CA, Ahuja N, Bylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res 2016;76:1683-1689.
62. Cai D, Wang X, Yan R, Mao R, Liu Y, Ji C, et al. Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. Antiviral Res 2016;132:26-37.
63. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014;13:673-691.
64. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 2011;1:519-525.
65. Janssen HL, Van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.
66. Kumar A, Darcis G, Van Lint C, Herbein G. Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics 2015;7:103.
67. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-1228.
68. Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, et al. G to A hypermutation of hepatitis B virus. Hepatology 2005;41:626-633.
69. Wachowska M, Muchowicz A, Golab J. Targeting epigenetic processes in photodynamic therapy-induced anticancer immunity. Front Oncol 2015;5:176.
70. Youngblood B, Hale JS, Ahmed R. T-cell memory differentiation: Insights from transcriptional signatures and epigenetics. Immunology 2013;139:277-284.
71. Li H, Chiappinelli KB, Guzzetta A, Easwaran H, Yen RW, Vatapalli R, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014;5:587-598.
72. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424-1433.
73. Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011;117:2910-2917.
74. Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 2016;150:194-205.